Hospital

Patients with perinatally-acquired HIV reported low emotional, instrumental, and friendship support at 37%, 32%, and 36%, respectively.

The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.

Participants were able to stop treatment after achieving amyloid plaque clearance and experience lasting results.

Therapeutic drug monitoring is a growing and vital area for pharmacists to become involved in to increase patient success with inflammatory bowel disease remission.

Though the overall significance of the results were low, vitamin D was found to be especially useful in lowering the prevalence of myocardial infarction in older adults.

Pharmacist-led discharge stewardship initiatives have shown promising results.

A significant proportion of patients had negative hepatitis B surface antibody titers, indicating a need for vaccination to ensure protection for patients undergoing hemodialysis.

The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.

High doses of intravenous immunoglobulin can result in expensive medical treatments for the families of children with immune thrombocytopenia.

Every pharmacist can make a difference in patients’ lives by taking the time to understand and fulfill the community’s social and cultural needs.

Chemotherapy may increase inflammatory biomarkers that can impact the diversity of the gut microbiome, leading to serious anthropomorphic changes among women treated for early-stage breast cancer.

A panel at the Advanced Topics for Oncology Pharmacy Professionals Summit discusses strategies to address patients’ fears and distrust of the medical and scientific community.

Effective implementation of the Inflation Reduction Act may allow legislators to shift their focus toward controversial pharmacy benefit manager practices, according to a panel discussion during the ATOPP Summit.

Zanubrutinib combined with obinutuzumab was previously granted both Fast Track and Orphan drug designations for patients with relapsed or refractory follicular lymphoma.

Despite a slew of barriers with patient management, pharmacists have the training and resources to advocate for better patient care and help patients with hematologic myeloproliferative neoplasms advocate for themselves.

Drug shortages have led to increased use of compounding pharmacy.

Study among the first to examine delayed or missed pediatric preventative care during COVID-19 that considers determinants, race, and ethnic group, according to the authors.

Quality standards and national regulation help to establish its role as medicine.

The practice has biologic, epigenetic, and structural implications on people living in these once-segregated areas.

Proof-of-concept device will be able to detect SARS-CoV-2 within minutes.

The approval makes remdesivir the first and only approved antiviral treatment for patients across all stages of renal disease.

Data show these cases pose some of the most significant threats to patients and health systems.

Because of its prevalence in approximately 50% of breast cancers, the outcomes of HER2-low treatment have a significant impact on patient outcomes.

Irreversible Bruton tyrosine kinase inhibitor produces positive results in patients with relapsed/refractory marginal zone lymphoma.

Evidence remains limited for specific therapies to treat the disease, but new clinical trials are ongoing.

Impact of healthy eating was especially evident in countries where consumption of these foods is low, which elevates the risk for cardiovascular disease, including heart attacks and strokes.

MicroRNA has shown the potential to more effectively and accurately identify C. difficile infections and manage it after diagnosis.

Express Scripts recently announced the addition of 3 Humira biosimilars to its main formulary.

Nivolumab-based combinations have shown significant survival benefits across several tumor types, including melanoma and advanced renal cell carcinoma.